查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細菌性陰道炎藥物市場規模及預測 2021 - 2031 年，全球及地區佔有率、趨勢及成長機會分析報告範圍：按類型、給藥途徑、劑型、配銷通路和地理分類
市場調查報告書
商品編碼
1666211

細菌性陰道炎藥物市場規模及預測 2021 - 2031 年，全球及地區佔有率、趨勢及成長機會分析報告範圍：按類型、給藥途徑、劑型、配銷通路和地理分類

Bacterial Vaginosis Drug Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 184 Pages | 訂單完成後即時交付

價格

依據「細菌性陰道炎藥物市場預測到 2031 年 - 全球分析 - 按類型、給藥途徑、劑型、配銷通路和地區」的新研究，市場預計將從 2024 年的 21.5 億美元成長到 2031 年的 38.2 億美元；預計 2024-2031 年期間的複合年成長率為 8.3%。細菌性陰道炎藥物市場規模的上升以及對開發新型標靶療法的日益關注，促進了細菌性陰道炎藥物市場規模的不斷擴大。然而，高復發率和治療依從性挑戰阻礙了細菌性陰道炎藥物市場的成長。此外，人們對微生物組療法和益生菌的日益關注預計將在未來幾年帶來新的細菌性陰道炎藥物市場趨勢。

就收入而言，北美在 2024 年佔據市場主導地位。美國是世界上最大的細菌性陰道炎藥物市場。在美國，由於細菌性陰道炎藥物市場正在經歷顯著上升、女性健康意識不斷增強以及不斷努力開發創新治療方法，細菌性陰道炎藥物市場正在經歷顯著成長。細菌性陰道炎 (BV) 是女性最常見的陰道感染之一，尤其影響育齡女性。根據Medscape在2024年的報告，美國每年約有三分之一的成年女性（約2,200萬名女性）受到細菌性陰道炎的影響，有1,000萬名女性因陰道分泌物異常而到診所就診。它通常與性活動、灌洗和荷爾蒙變化等因素有關；儘管如此，細菌性陰道炎的具體病因仍不確定。治療細菌性陰道炎 (BV) 的主要治療選擇包括美國食品藥物管理局 (FDA) 批准的抗生素，例如甲硝唑和克林黴素。甲硝唑通常以口服和外用形式提供，被認為是治療細菌性陰道炎的第一線藥物。克林黴素通常以口服和外用兩種劑型提供。益生菌和噬菌體療法等較新的藥物和製劑也正在出現，有助於恢復天然陰道菌群，從而減少細菌性陰道炎的復發。

美國政府的措施在提高和傳播民眾對陰道病的認知方面發揮了關鍵作用。美國國立衛生研究院 (NIH) 資助細菌性陰道炎的病因、治療和預防的研究。美國國立衛生研究院的努力使我們對微生物群及其在導致細菌性陰道炎中的作用有了更深入的了解，這對於開發更有針對性的治療方法至關重要。美國疾病管制與預防中心 (CDC) 提供了指南和建議，以改善 BV 的診斷和管理。這些措施有助於標準化護理並確保患者得到最有效的治療。此外，美國國家兒童健康與人類發展研究所（NICHD，一個聯邦機構）和美國國立衛生研究院致力於了解細菌性陰道炎，並教育女性了解其原因和預防措施。 NICHD 資助並進行與 BV 相關的風險以及預防和治療方法的研究。

細菌性陰道炎藥物市場分析

市場參與者的策略性措施為未來提供市場機會

在細菌性陰道炎藥物市場營運的公司不斷關注策略發展，例如產品批准、合作、資金、協議和新產品發布，這有助於他們提高銷售額、擴大地理覆蓋範圍並增強其滿足現有客戶群的能力。以下提到了細菌性陰道炎藥物市場的主要參與者的一些策略性舉措。

2024年11月，Freya Biosciences獲得比爾和梅琳達蓋茲基金會1,040萬美元的策略性投資，並從現有投資者丹麥出口和投資基金（EIFO）獲得140萬美元的額外融資。該公司計劃利用這些資金開發治療 BV 的微生物免疫療法，以解決早產風險以及其他可能影響產婦和新生兒健康的疾病。

2022 年 3 月，Organon 與 Dare Bioscience, Inc. 達成協議，根據該協議，Organon 將授予 XACIATO（克林黴素磷酸鹽陰道凝膠，2%）的全球權利。憑藉此產品，XACIATO 獲得了美國食品藥物管理局 (FDA) 頒發的用於治療細菌性陰道炎的合格傳染病產品 (QIDP) 和快速通道資格。

2022年2月，Lupin Pharmaceuticals Inc.取得FDA核准補充新藥申請（sNDA），以增加SOLOSEC（塞克硝唑）在12歲或以上女性病患治療BV的使用；該批准還涉及對上述年齡層患者的滴蟲病進行治療。

2021年12月，FDA批准了Dare Bioscience, Inc.生產的XACIATO（克林黴素磷酸鹽陰道凝膠，2%）用於治療12歲以上女性的細菌性陰道炎。

2021 年 2 月，Rebiotix（Ferring）和 MyBiotics 合作開發基於活微生物組的治療方法，用於生殖醫學和孕產婦健康。此次合作旨在打造以活微生物為基礎的生物療法藥物，用於治療育齡婦女的細菌性陰道炎，這種疾病可能與流產風險增加以及懷孕及生育併發症有關。

因此，持續的資金、產品發布和批准以及合作預計將為未來幾年細菌性陰道炎藥物市場的成長創造充足的機會。

細菌性陰道炎藥物市場報告細分分析

有助於得出細菌性陰道炎藥物市場分析的關鍵部分是類型、給藥途徑、劑型和配銷通路。

根據類型，細菌性陰道炎藥物市場分為處方藥和非處方藥。 2024 年，處方藥市場將佔據更大的佔有率。

根據給藥途徑，細菌性陰道炎藥物市場分為口服、陰道和外用。 2024 年，口服藥物將佔據市場主導地位。

就劑型而言，細菌性陰道炎藥物市場分為丸劑、乳膏、凝膠、溶液/洗劑等。 2024 年，藥丸類產品佔據市場主導地位。

從配銷通路來看，細菌性陰道炎藥物市場分為醫院藥房、網路藥房和零售藥房。 2024 年，醫院藥局部門將佔據市場主導地位。

細菌性陰道炎藥物市場：競爭格局與關鍵發展

拜耳股份公司、輝瑞公司、賽諾菲公司、Starpharma Holdings Limited、Viatris Inc、Glenmark Pharmaceuticals Ltd、Lupin Ltd、Sun Pharmaceutical Industries Ltd、Organon & Co、Duchesnay Inc.、加拿大是細菌性陰道炎藥物市場的主要公司。

《歐洲婦產科和生殖生物學雜誌》、美國國立衛生研究院、Medscape、加拿大政府、聯合國2024年世界人口展望、歐盟統計局、歐盟委員會、澳洲政府衛生和老年護理部、世界銀行和國際貿易管理局是編寫細菌性陰道炎藥物市場報告時參考的主要和次要來源。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 發育基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：細菌性陰道炎藥物市場格局

  • 概述
  • PEST分析
  • 發生率：細菌性陰道炎

第 5 章：細菌性陰道炎藥物市場 - 主要市場動態

  • 細菌性陰道炎藥物市場 - 主要市場動態
  • 市場促進因素
    • 細菌性陰道炎症率上升
    • 更加重視開發新型標靶療法
  • 市場限制
    • 高復發率和治療依從性的挑戰
  • 市場機會
    • 市場參與者的策略性舉措
  • 未來趨勢
    • 人們對微生物組療法和益生菌的興趣日益濃厚
  • 促進因素和限制因素的影響：

第 6 章：細菌性陰道炎藥物市場 - 全球市場分析

  • 細菌性陰道炎藥物市場收入，2021-2031 年
  • 細菌性陰道炎藥物市場預測分析

第 7 章：細菌性陰道炎藥物市場分析 - 按類型

  • 處方藥 (Rx)
  • 非處方藥 (OTC)

第 8 章：細菌性陰道炎藥物市場分析 - 按給藥途徑

  • 口服
  • 陰道
  • 主題

第 9 章：細菌性陰道炎藥物市場分析 - 按劑型

  • 藥丸
  • 乳霜
  • 凝膠
  • 溶液或清洗液
  • 其他

第 10 章：細菌性陰道炎藥物市場分析 - 按配銷通路

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章：細菌性陰道炎藥物市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 概述
  • 細菌性陰道炎藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • Bayer AG
  • Pfizer Inc
  • Sanofi SA
  • Starpharma Holdings Limited
  • Viatris Inc
  • Glenmark Pharmaceuticals Ltd
  • Lupin Ltd
  • Sun Pharmaceutical Industries Ltd
  • Organon & Co
  • Duchesnay Inc., Canada

第 14 章：附錄

Product Code: TIPRE00018820

According to our new research study on "Bacterial Vaginosis Drug Market Forecast to 2031 -Global Analysis - by Type, Route of Administration, Dosage Form, and Distribution Channel, and Geography," the market is anticipated to grow from US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is expected to register a CAGR of 8.3% during 2024-2031. Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing Bacterial Vaginosis Drug market size. However, the high recurrence rate and treatment adherence challenges hampers the Bacterial Vaginosis Drug market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to bring in new Bacterial Vaginosis Drug market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for bacterial vaginosis drugs in the world. In the US, the bacterial vaginosis drug market is experiencing significant growth due to the increasing prevalence of BV, rising awareness about women's health, and ongoing efforts for the development of innovative treatments. BV is one of the most common vaginal infections in women, particularly affecting those of reproductive age. According to a report by Medscape in 2024, approximately one-third of adult women in the US, i.e., ~22 million females, are affected by BV annually, and 10 million women visit clinics for abnormal vaginal discharge. It is often linked to factors such as sexual activity, douching, and hormonal changes; nonetheless, there is uncertainty around the exact causes of BV. The primary therapeutic options available for treating BV include antibiotics approved by the US Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole, often available in oral and topical forms, is considered the first-line treatment for BV. Clindamycin is also commonly available in both oral and topical formulations. Newer drugs and formulations, such as probiotics and phage therapy, are also emerging to help restore the natural vaginal flora, thereby reducing the recurrence of BV.

Government initiatives in the US play a key role in creating and spreading awareness about vaginosis in the population. The National Institutes of Health (NIH) funds research into the causes, treatment, and prevention of BV. The NIH's efforts have led to a deeper understanding of the microbiome and its role in causing BV, which is crucial for developing more targeted therapies. Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations to improve the diagnosis and management of BV. These initiatives help standardize care and ensure that patients receive the most effective treatment. Additionally, the National Institute of Child Health and Human Development (NICHD, a federal agency) and NIH are dedicated to understanding BV and educating women about its causes and prevention. NICHD funds and conducts research on the risks associated with BV and methods for its prevention and treatment.

Bacterial Vaginosis Drug Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the bacterial vaginosis drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the bacterial vaginosis drugs market are mentioned below.

In November 2024, Freya Biosciences received US$ 10.4 million in strategic investment from the Bill & Melinda Gates Foundation, with US$ 1.4 million in additional financing from the current investor-Export and Investment Fund of Denmark (EIFO). The company plans to use these funds to develop microbial immunotherapies for the treatment of BV to address the risk of preterm birth along with other indications potentially affecting maternal and newborn health.

In March 2022, Organon and Dare Bioscience, Inc. entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). With this, XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis.

In February 2022, Lupin Pharmaceuticals Inc. received FDA approval for a supplemental New Drug Application (sNDA) to increase the use of SOLOSEC (secnidazole) for the treatment of BV among female patients aged 12 or older; the approval also entailed the treatment of trichomoniasis among patients from the said age group.

In December 2021, the FDA approved XACIATO (clindamycin phosphate vaginal gel, 2%) manufactured by Dare Bioscience, Inc. for the treatment of bacterial vaginosis in females of age 12 years or more.

In February 2021, Rebiotix (Ferring) and MyBiotics collaborated to develop live microbiome-based therapeutics for applications in reproductive medicine and maternal health. This collaboration aims to create live microbiota-based biotherapeutics for bacterial vaginosis among women of childbearing age, which may be associated with the increased risk of miscarriage and complications in pregnancy and fertility.

Therefore, ongoing funding, product launches and approvals, and collaborations are expected to create ample opportunities for the growth of the bacterial vaginosis drugs market in the coming years.

Bacterial Vaginosis Drug Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Bacterial Vaginosis Drug market analysis are type, route of administration, dosage form, and distribution channel.

Based on type, the bacterial vaginosis drug market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger share of the market in 2024.

In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024.

In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gels, solutions/washes, and others. The pills segment dominated the market in 2024.

In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Bacterial Vaginosis Drug Market: Competitive Landscape and Key Developments

Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key companies operating in the Bacterial Vaginosis Drug market.

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government's Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the Bacterial Vaginosis Drug market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Bacterial Vaginosis Drug Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Incidence Rate: Bacterial Vaginosis

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

  • 5.1 Bacterial Vaginosis Drug Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Bacterial Vaginosis
    • 5.2.2 Increased Focus on Developing Novel and Targeted Therapies
  • 5.3 Market Restraints
    • 5.3.1 High Recurrence Rate and Treatment Adherence Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Market Players
  • 5.5 Future Trends
    • 5.5.1 Rising Inclination Toward Microbiome Therapies and Probiotics
  • 5.6 Impact of Drivers and Restraints:

6. Bacterial Vaginosis Drug Market - Global Market Analysis

  • 6.1 Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
  • 6.2 Bacterial Vaginosis Drug Market Forecast Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

  • 7.1 Prescription Drugs (Rx)
    • 7.1.1 Overview
    • 7.1.2 Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Over-the-counter Drugs (OTC)
    • 7.2.1 Overview
    • 7.2.2 Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Vaginal
    • 8.2.1 Overview
    • 8.2.2 Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Topical
    • 8.3.1 Overview
    • 8.3.2 Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

  • 9.1 Pills
    • 9.1.1 Overview
    • 9.1.2 Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Creams
    • 9.2.1 Overview
    • 9.2.2 Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Gel
    • 9.3.1 Overview
    • 9.3.2 Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Solution or Washes
    • 9.4.1 Overview
    • 9.4.2 Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Online Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Retail Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

11. Bacterial Vaginosis Drug Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Bacterial Vaginosis Drug Market Overview
    • 11.1.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.1.2.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.1.2.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.1.2.4 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.2 United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 United States: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.2.2 United States: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.2.3 United States: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.2.4 United States: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.1.3.3 Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Canada: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.3.2 Canada: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.3.3 Canada: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.3.4 Canada: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.1.3.4 Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.4.1 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.1.3.4.2 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.1.3.4.3 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.1.3.4.4 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Bacterial Vaginosis Drug Market Overview
    • 11.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.2.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.2.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.2.2.4 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.2 Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 Germany: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.2.2 Germany: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.2.3 Germany: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.2.4 Germany: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.3 United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.3.2 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.3.3 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.3.4 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.4 France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 France: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.4.2 France: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.4.3 France: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.4.4 France: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.5 Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 Spain: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.5.2 Spain: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.5.3 Spain: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.5.4 Spain: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.6 Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Italy: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.6.2 Italy: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.6.3 Italy: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.6.4 Italy: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.2.3.7 Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.7.1 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.2.3.7.2 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.2.3.7.3 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.2.3.7.4 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Bacterial Vaginosis Drug Market Overview
    • 11.3.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.3.2.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.3.2.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.3.2.4 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.2 China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 China: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.2.2 China: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.2.3 China: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.2.4 China: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.3 Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 Japan: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.3.2 Japan: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.3.3 Japan: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.3.4 Japan: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.4 India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 India: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.4.2 India: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.4.3 India: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.4.4 India: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.5 Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 Australia: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.5.2 Australia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.5.3 Australia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.5.4 Australia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.6 South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.6.2 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.6.3 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.6.4 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.3.3.7 Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.7.1 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.3.3.7.2 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.3.3.7.3 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.3.3.7.4 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Bacterial Vaginosis Drug Market Overview
    • 11.4.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.4.2.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.4.2.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.4.2.4 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.2 Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.2.2 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.2.3 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.2.4 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.3 South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.3.2 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.3.3 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.3.4 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.4 United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.4.2 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.4.3 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.4.4 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.4.3.5 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.5.1 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.4.3.5.2 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.4.3.5.3 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.4.3.5.4 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Bacterial Vaginosis Drug Market Overview
    • 11.5.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
      • 11.5.2.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
      • 11.5.2.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
      • 11.5.2.4 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.2 Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.2.2 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.2.3 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.2.4 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.5.3.3 Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.3.2 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.3.3 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.3.4 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
      • 11.5.3.4 Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.4.1 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Type
        • 11.5.3.4.2 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
        • 11.5.3.4.3 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
        • 11.5.3.4.4 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Bacterial Vaginosis Drug Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Bayer AG
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Pfizer Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Starpharma Holdings Limited
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Viatris Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Glenmark Pharmaceuticals Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Lupin Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Sun Pharmaceutical Industries Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Organon & Co
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Duchesnay Inc., Canada
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms for Bacterial Vaginosis Drug Market

List Of Tables

  • Table 1. Bacterial Vaginosis Drug Market Segmentation
  • Table 2. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Type
  • Table 3. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Route of Administration
  • Table 4. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Dosage Form
  • Table 5. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 7. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 8. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 9. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 11. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 13. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 14. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 15. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 16. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 17. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 18. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 19. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 20. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 21. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 22. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 23. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 24. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 25. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 26. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 28. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 30. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 31. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 32. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 34. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 35. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 36. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 37. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 38. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 39. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 40. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 41. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 42. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 43. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 44. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 45. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 46. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 47. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 48. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 49. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 50. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 51. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 52. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 53. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 54. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 55. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 56. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 57. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 58. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 59. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 60. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 61. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 62. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 63. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 64. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 65. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 66. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 67. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 68. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 69. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 70. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 71. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 72. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 73. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 74. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 75. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 76. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 77. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 78. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 79. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 80. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 81. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 82. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 83. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 84. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 85. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 86. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 87. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 88. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 89. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 91. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 92. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 93. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 95. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 96. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 97. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 99. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 100. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 101. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 103. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 104. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 105. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 107. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 108. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 109. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 110. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 111. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 112. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 113. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 114. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 115. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 116. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
  • Table 117. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
  • Table 118. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 119. Recent Organic Growth Strategies in the Bacterial Vaginosis Drug Market
  • Table 120. Recent Inorganic Growth Strategies in the Bacterial Vaginosis Drug Market
  • Table 121. Glossary of Terms

List Of Figures

  • Figure 1. Bacterial Vaginosis Drug Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
  • Figure 5. Bacterial Vaginosis Drug Market Share (%) - by Type (2024 and 2031)
  • Figure 6. Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Bacterial Vaginosis Drug Market Share (%) - by Route of Administration (2024 and 2031)
  • Figure 9. Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Bacterial Vaginosis Drug Market Share (%) - by Dosage Form (2024 and 2031)
  • Figure 13. Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Bacterial Vaginosis Drug Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 19. Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 23. North America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 24. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 25. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Europe: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Asia Pacific: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 37. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 45. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 51. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Growth Strategies in the Bacterial Vaginosis Drug Market